NEURAXPHARM LAUNCHES FIRST PRODUCT IN JAPAN

Neuraxpharm launches first product in Japan

Launch of Buccolam® – market leading product for emergency treatment of children with epilepsy suffering from prolonged acute convulsive seizures – following recent acquisition from Takeda

First buccal midazolam to receive approval in Japan, world’s second largest central nervous system market [1]

Düsseldorf and Barcelona, January, 12, 2021 – Neuraxpharm Group (Neuraxpharm), a leading European specialty pharmaceutical company focused on the central nervous system (CNS), today announces the launch in Japan of the recently acquired prescription brand Buccolam® (oromucosal midazolam) following its approval as the first buccally administered formulation for the treatment of status epilepticus (SE) in the country.

Read more….

By Optimum

For more information about Optimum Strategic Communications, please get in touch

We'd love to hear from you...

GET IN TOUCH